Tenaya Therapeutics (TNYA) director granted stock options for 120,000 shares
Rhea-AI Filing Summary
Tenaya Therapeutics director Jeffrey T. Walsh received a stock option grant covering 120,000 shares of common stock at an exercise price of $0.7989 per share. The option was granted under the company’s 2021 Equity Incentive Plan, vests in full on May 28, 2027 (or earlier, before the next annual stockholder meeting), and expires on May 27, 2036. This filing reports an award of options rather than any open-market share purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Walsh Jeffrey T.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to buy) | 120,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to buy) — 120,000 shares (Direct)
Footnotes (1)
- F1. Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.
Key Figures
Option shares granted: 120,000 shares
Exercise price: $0.7989 per share
Underlying common shares: 120,000 shares
+3 more
6 metrics
Option shares granted
120,000 shares
Stock Option grant to Jeffrey T. Walsh
Exercise price
$0.7989 per share
Stock Option strike price
Underlying common shares
120,000 shares
Common stock underlying the option
Post-transaction derivative holdings
120,000 options
Total derivative shares following transaction
Vesting date
May 28, 2027
Option vests in full or earlier before next annual meeting
Expiration date
May 27, 2036
Option expiration
Key Terms
Stock Option (Right to buy), Equity Incentive Plan, vesting, service provider
4 terms
Stock Option (Right to buy) financial
"security_title: Stock Option (Right to buy)"
Equity Incentive Plan financial
"Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
vesting financial
"Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
service provider financial
"subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Tenaya Therapeutics (TNYA) director Jeffrey T. Walsh report in this Form 4?
Jeffrey T. Walsh reported receiving a stock option grant for 120,000 shares of Tenaya common stock. The award is documented as a derivative acquisition, not an open-market trade, and is tied to future vesting and service conditions under the company’s equity plan.
What is the exercise price and term of Jeffrey Walsh’s Tenaya Therapeutics (TNYA) stock option?
The option has an exercise price of $0.7989 per share and expires on May 27, 2036. This defines the price Walsh can pay for the shares and the final date the option can be exercised, assuming it has vested and other conditions are met.
When does Jeffrey Walsh’s Tenaya Therapeutics (TNYA) option vest according to the Form 4?
The option will vest in full on May 28, 2027, or earlier, the day immediately before the next annual stockholder meeting after the grant date. Vesting depends on Walsh continuing to be a service provider to Tenaya through the applicable vesting date.
Was Jeffrey Walsh’s Tenaya Therapeutics (TNYA) option grant part of a company equity plan?
Yes. The footnote states the option was granted under the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Such plans set the terms for equity-based awards granted to eligible service providers of the company.